It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Shifts in normal aging set stage for neurodegeneration and dementia affecting 1 in 10 adults. The study demonstrates that lncRNA GAS5 is decreased in aged and Alzheimer’s disease brain. The role and targets of lncRNA GAS5 in the aging brain were elucidated using a GAS5-targeting small molecule NPC86, a frontier in lncRNA-targeting therapeutic. Robust techniques such as molecular dynamics simulation of NPC86 binding to GAS5, in vitro functional assays demonstrating that GAS5 regulates insulin signaling, neuronal survival, phosphorylation of tau, and neuroinflammation via toll-like receptors support the role of GAS5 in maintaining healthy neurons. The study demonstrates the safety and efficacy of intranasal NPC86 treatment in aged mice to improve cellular functions with transcriptomic analysis in response to NPC86. In summary, the study demonstrates that GAS5 contributes to pathways associated with neurodegeneration and NPC86 has tremendous therapeutic potential to prevent the advent of neurodegenerative diseases and dementias.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 James A. Haley Veterans Hospital, Research Service, Tampa, USA (GRID:grid.281075.9) (ISNI:0000 0001 0624 9286)
2 University of South Florida, Department of Molecular Medicine, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X)
3 University of South Florida, Department of Neurosurgery and Brain Repair, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X)
4 UMass Chan Medical School, Worcester, USA (GRID:grid.170693.a)
5 University of South Florida, Department of Molecular Medicine, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X); University of South Florida, USF Health Byrd Institute, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X)
6 University of South Florida, Department of Chemistry, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X)
7 James A. Haley Veterans Hospital, Research Service, Tampa, USA (GRID:grid.281075.9) (ISNI:0000 0001 0624 9286); University of South Florida, Department of Molecular Medicine, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X); University of South Florida, USF Health Byrd Institute, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X)
8 James A. Haley Veterans Hospital, Research Service, Tampa, USA (GRID:grid.281075.9) (ISNI:0000 0001 0624 9286); University of South Florida, Department of Neurosurgery and Brain Repair, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X)
9 James A. Haley Veterans Hospital, Research Service, Tampa, USA (GRID:grid.281075.9) (ISNI:0000 0001 0624 9286); University of South Florida, Department of Molecular Medicine, Tampa, USA (GRID:grid.170693.a) (ISNI:0000 0001 2353 285X)